39 results about "Risk of mortality" patented technology

The invention relates to a method and apparatus for predicting a sudden heart abnormality for an individual patient. In order to provide a prediction mechanism that is suitable for acute care, three sub-indices are determined based on medical data obtained from the patient. The first sub-index indicates the level of deterministic chaos in the heart rate variability of the patient, the second sub-index indicates the energy level in the myocardium of the patient, and the third sub-index indicates the degree of ventricular arrhythmia of the patient. Based on the first, second, and third sub-indices, at least one overall risk index is then determined, the overall risk index indicating the risk level of a sudden heart abnormality for the patient.

Biomarkers for sepsis and resulting mortality can be detected by assaying blood samples. Changes in the concentration of the biomarkers can be used to indicate sepsis, risk of sepsis, progression of sepsis, remission from sepsis, and risk of mortality. Changes can be evaluated relative to data sets, natural or synthetic or semisynthetic control samples, or patient samples collected at different time points. Some biomarkers' concentrations are elevated during disease and some are depressed. These are termed informative biomarkers. Some biomarkers are diagnostic in combination with others. Individual biomarkers may be weighted when used in combinations. Biomarkers can be assessed in individual, isolated or assays, in parallel assays, or in single-pot assays.

A system and method for assessing a patient's risk of sudden cardiac death. One method of the invention can include acquiring patient data at one of a plurality of healthcare locations, identifying the patient as being worthy of an on-going sudden cardiac death risk assessment based on the acquired patient data, and performing the on-going sudden cardiac death risk assessment whenever new patient data is acquired at any one of the plurality of healthcare locations.

The invention relates to a method and apparatus for predicting a sudden heart abnormality for an individual patient. In order to provide a prediction mechanism that is suitable for acute care, three sub-indices are determined based on medical data obtained from the patient. The first sub-index indicates the level of deterministic chaos in the heart rate variability of the patient, the second sub-index indicates the energy level in the myocardium of the patient, and the third sub-index indicates the degree of ventricular arrhythmia of the patient. Based on the first, second, and third sub-indices, at least one overall risk index is then determined, the overall risk index indicating the risk level of a sudden heart abnormality for the patient.

Methods of classifying risk and adjusting policy pricing for elderly insurance applicants are provided. The methods preferably include the steps of requesting the applicant to perform tests in addition to a physical examination, analyzing the results of the tests, and classifying the risk of mortality of the applicant based on the results of the analysis. The additional test is preferably designed to analyze the applicant's physical performance, cognitive performance, executive function, and present physical health of an applicant.

A congestive heart failure (CHF) mortality risk metric is automatically generated using an implantable medical device and, if it exceeds a predetermined threshold, a warning signal is issued indicating a significant risk of mortality due to CHF, perhaps necessitating more aggressive medical therapy. The CHF mortality risk metric is calculated based on a combination of estimated ventilatory response values and the slope of heart rate reserve as a function of predicted heart rates. Ventilatory response is estimated based on detected values of actual heart rate, arterial oxygen saturation, right ventricular O2, stroke volume, tidal volume, and respiration rate. Heart rate reserve values are derived from the actual heart rate along with patient age and rest heart rate. The predicted heart rates, which represent the heart rates the patient would achieve if healthy, are derived from activity sensor signals. The CHF mortality risk metric is then calculated as a ratio of ventilatory response and the slope of the heart rate reserve. If the CHF mortality risk metric exceeds a critical threshold value, such as 90, the warning signal is generated. Also described herein are various techniques for estimating ventilatory response.

The present invention provides for methods of determining telomere length of an organism and correlating the measured telomere length with mortality risk associated with telomere length in a population. The presence of shorter telomeres is associated with an increased mortality rate and increased susceptibility to certain types of diseases for an individual member of a human population.

The present invention relates to a method of identifying a subject being susceptible to a cardiac intervention based on the determination of GDF-15 in a sample of a subject in need of a cardiac intervention. Moreover, the present invention pertains to a method for predicting the risk of mortality or a further acute cardiovascular event for a subject suffering from a cardiovascular complication based on the determination of GDF-15 and a natriuretic peptide and / or a cardiac troponin in a sample the said subject. Also encompassed by the present invention are devices and kits for carrying out the aforementioned methods.

Techniques are described for use by a pacemaker or implantable cardioverter / defibrillator (ICD) or other implantable medical device. The techniques are provided for evaluating the likelihood that the patient, in which the device is implanted, has impaired glucose tolerance (IGT) or diabetes mellitus. Briefly, a value representative of sleep quality of the patient is detected and then the likelihood that the patient has IGT or diabetes mellitus is determined based on the sleep quality value. In this regard, it has been found that a decrease in overall sleep quality is associated with an increased likelihood of IGT or diabetes mellitus, which is in turn associated with an increased risk of mortality. Hence, sleep quality may be used as a proxy for evaluating the likelihood that the patient has IGT or diabetes mellitus and for assessing associated mortality risk.

Described is a method of identifying if a subject is to be admitted to the hospital or intensive care unit, the method comprising a) determining the amount of GDF 15 in a sample of the subject, and b) comparing the amount of GDF 15 determined in step a) to a reference amount, whereby a subject to be admitted to the hospital or intensive care unit is to be identified. Also described is a method for predicting the risk of mortality based on determining the amount of GDF 15 in a subject. Also described are devices and kits for carrying out the aforementioned methods.

The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's systolic blood pressure, serum albumin level, body weight, and body temperature at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the patient has a substantial change in the rate of decline of at least one of the patient's systolic blood pressure, serum albumin level, body weight, and body temperature. The invention is also directed to a method of identifying an increased mortality risk factor for a patient undergoing periodic hemodialysis treatment. The method includes analyzing data in deceased patients that were previously undergoing periodic hemodialysis treatments by performing a longitudinal analysis backwards in time of changes in a clinical or biochemical parameter the patients, and identifying a substantial change in the rate of decline or the rate of increase in a clinical or biochemical parameter before death of the patients.

The invention relates to a biological marker and a method for diagnosing or estimating mortality risk. The biological marker comprises at least one group of the following characteristic genomes: SigCYBDEGBC, SigCYBDEGBC1, SigCYBDEGBC2, SigCYBDEGBC3, SigCutpnt, SigBasa1, SigClaudin, SigNorm, SigLumB and SingLumA. The biological marker has the advantage that forward survival and prognosis of breastcancer patients can be estimated effectively.

The invention discloses a biomarker and a method for predicating relapse and mortality risk of renal cell carcinoma, and belongs to the renal cell monitoring technology. The biomarker is used for predicating the relapse or mortality risk of a patient with renal cell carcinoma after tumor is resected. The biomarker is one of the following characteristic genomes: Sig2.5, Sig0.83, Sig0.83sub1, Sig0.83sub2 and Sigcmbn; the relapse or mortality risk of the patient with renal cell carcinoma can be predicated by detecting the expression condition of the characteristic genomes in the biomarker. The biomarker has the advantages of being capable of effectively estimating the relapse or mortality risk of the patient with renal cell carcinoma after tumor is resected, so that the patient management canbe greatly performed; and novel assistant treatment or targeted treatment can be specifically performed on some patients with high relapse or mortality risk.

The present invention provides for methods of determining telomere length of an organism and correlating the measured telomere length with mortality risk associated with telomere length in a population. The presence of shorter telomeres is associated with an increased mortality rate and increased susceptibility to certain types of diseases for an individual member of a human population.

The present invention relates to methods for preventing or reducing the risk of mortality by any means including, but not limited to, cardiovascular events in mammals, particularly humans, comprising administering a dipeptidyl peptidase 4 (DPP-IV) inhibitor to the mammal or human. In addition, the present invention relates to methods for preventing or reducing the risk of non-fatal myocardial infarction and / or non-fatal stroke in mammals, particularly humans, comprising administering a DPP-IV inhibitor to the mammal or human.

The invention comprises a system and method for hedging or mitigating mortality exposure risk in a portfolio of mortality-dependent instruments. A mortality risk or longevity risk of the portfolio is calculated or otherwise determined. Then the sensitivity of the portfolio to mortality risk or longevity risk is calculated or otherwise determined, in other words, how much is cost or value of the portfolio affected by a change in mortality rate. To account for that mortality exposure, a selection is made of building block mortality derivatives that include age-based mortality derivatives. The selected plurality of building block mortality derivatives are used to create a hedge against the mortality risk or longevity risk of the portfolio.

Among the various aspects of the present disclosure is the provision of a method of detecting ceramides as prognostic indicators. An aspect of the present disclosure provides for a prognostic indicator for risk of developing a cardiovascular-related disease, disorder, or condition and mortality risk.

Provided are a method for predicting a mortality risk or a sepsis risk, implemented by a processor, to predict an emergency situation, and a device using the same. The method for predicting a mortality risk or a sepsis risk includes: receiving biological signal data for a subject from a biological signal prediction device; generating a risk sequence for the subject based on the biological signal data, by using a risk sequence generation model configured to generate a risk sequence based on the biological signal data; and predicting a risk for the subject based on the risk sequence.

The present invention relates to methods for preventing or reducing the risk of mortality by any means including, but not limited to, cardiovascular events in mammals, particularly humans, comprising administering a dipeptidyl peptidase 4 (DPP-IV) inhibitor to the mammal or human. In addition, the present invention relates to methods for preventing or reducing the risk of non-fatal myocardial infarction and / or non-fatal stroke in mammals, particularly humans, comprising administering a DPP-IV inhibitor to the mammal or human.

The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and / or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and / or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.

A method of treatment using carvedilol is disclosed, wherein the carvedilol decreases the risk of mortality caused by congestive heart failure in patients. The patients are titrated with low amounts of carvedilol, with the initial titration dosage being only 10 to 30% of the daily maintenance dose.

The present invention relates to the discovery that an increased fraction of albumin is carbamylated in patients suffering from kidney disease (e.g., end-stage renal disease) and that the fraction of carbamylated albumin is also correlated with increased disease severity, particularly risk of mortality. The present invention also relates to the discovery that free amino acids can reduce carbamylation of albumin. Based on these discoveries the present invention provides diagnostic and prognostic methods for patients suffering from, or suspected of suffering from kidney disease. The invention also provides methods for treating kidney disease by administration of a compound or composition that reduced protein carbamylation, such as free amino acids or dipeptides.

The present invention includes novel methods of using a calcification risk index (CRI) for identifying or monitoring a patient with increased risk of cardiovascular calcification and / or mortality, or monitoring an effect of therapeutic treatment for a patient having cardiovascular calcification or with increased risk of cardiovascular calcification. The methods may include determining an alpha-2 HS glycoprotein level or circulating calcification inhibitory capacity in a biological sample, and comparing the level to at least one of the parameters selected from a calcium level, a phosphate level and a calcium×phosphate product level, or the combination of these values. The present invention may allow one able to identify or monitor a patient having increased risk of cardiovascular calcification and / or predicting mortality, or to monitor an effect of treatment for a patient having an increased risk of cardiovascular calcification or a patient who already has cardiovascular calcification.

Biomarkers for sepsis and resulting mortality can be detected by assaying blood samples. Changes in the concentration of the biomarkers can be used to indicate sepsis, risk of sepsis, progression of sepsis, remission from sepsis, and risk of mortality. Changes can be evaluated relative to data sets, natural or synthetic or semisynthetic control samples, or patient samples collected at different time points. Some biomarkers' concentrations are elevated during disease and some are depressed. These are termed informative biomarkers. Some biomarkers are diagnostic in combination with others. Individual biomarkers may be weighted when used in combinations. Biomarkers can be assessed in individual, isolated or assays, in parallel assays, or in single-pot assays.

The present invention relates to a method for diagnosis of a cardiovascular disease or condition or atherosclerosis and for a method for evaluating the risk of a subject of developing the same. Methods are further provided for evaluating a subject's risk of mortality, for evaluating whether a subject will benefit from a certain treatment or whether a subject needs to be hospitalized or whether a subject may be discharged. The present invention provides sCD14 or a fragment or derivative thereof (including in particular sCD14-ST) as a novel marker for cardiovascular risk in general, more specifically as a marker for cardiovascular disease or condition, or atherosclerosis.

A method for assessing prognosis in an individual suffering from liver failure, which method comprises detecting endotoxin in the individual, for example by determining the neutrophil function in the individual. The method can be used to determine whether there is an increased risk of infection in the individual, an increased risk of organ failure in the individual, an increased risk of mortality in the individual and / or an increased risk that the individual will not respond positively to treatment with an immunosuppressive agent, a steroid or an antibiotic.

The disclosure relates to a method of determining risk of mortality from Acute Lung Injury (ALI), sepsis, or a combination thereof in a patient, as well as a method of diagnosing ALI in a patient with sepsis based on the presence of tyrosine-nitrated sphingosine 1-phosphate 3 receptor (S1P3R) protein. The disclosure additionally relates to a method of treating an Acute Lung Injury (ALI) patient with sepsis based on the presence of tyrosine-nitrated S1P3R protein.

Methods and systems disclosed herein utilize an automated analytics framework to implement a perioperative complication risk algorithm that uses existing clinical data in electronic health records to forecast patient-level probabilistic risk scores for eight major postoperative complications. An example method includes accessing health record data for a patient, normalizing the accessed health record data to generate a health record data set for the patient, transforming one or more features from the health record data set, selecting one or more transformed features from the health record data set, calculating risk probabilities for one or more complication risk categories based on the health record data set and the selected one or more features, calculating mortality risk probabilities for one or more mortality risk categories based on the calculated risk probabilities, and generating a personalized risk panel based on the calculated risk probabilities and the calculated mortality risk probabilities.

The present invention is concerned with a method for predicting the risk of mortality and / or a cardiovascular event in a subject who suffers from the metabolic syndrome based on the determination of a natriuretic peptide and adiponectin in a sample of a subject. Moreover, the present invention relates to a method for identifying a subject being susceptible to a therapy that intends to increase the level of adiponectin in a subject based on the determination of the aforementioned markers. Further disclosed are kits and devices adapted to carry out the method of the present invention.